Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 + osimertinib vs osimertinib as neoadjuvant therapy in resectable EGFR-mutant NSCLC
ChiCTR2500113154Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Nov 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing SYS6010 + osimertinib with Osimertinib (2 arms). Primary endpoint: Major pathological response (MPR) rate difference by BIPR. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CPO301osimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500113154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113154.